Dynavax to Participate in the 2025 Wells Fargo Healthcare Conference

Rhea-AI Summary

Dynavax Technologies (Nasdaq: DVAX), a commercial-stage biopharmaceutical company focused on innovative vaccine development, will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on September 3rd at 4:30 p.m. ET.

The company currently markets two key products: HEPLISAV-B, an approved hepatitis B vaccine for adults in the US, EU, and UK, and CpG 1018 adjuvant, which is used in HEPLISAV-B and various COVID-19 vaccines.

News Market Reaction – DVAX

+0.10%

+0.10% Session close to close

In the Aug 28 session, DVAX gained 0.10%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

EMERYVILLE, Calif., Aug. 27, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3rd at 4:30 p.m. ET.

The presentations will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations.

About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B^® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and the United Kingdom for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018^® adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about our marketed products and development pipeline, visit www.dynavax.com.

For Investors/Media:
Paul Cox
pcox@dynavax.com
510-665-0499

Nicole Arndt
narndt@dynavax.com
510-665-7264

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-participate-in-the-2025-wells-fargo-healthcare-conference-302540380.html

SOURCE Dynavax Technologies

FAQ

When is Dynavax (DVAX) presenting at the Wells Fargo Healthcare Conference 2025?

Dynavax will participate in a fireside chat on Wednesday, September 3rd, 2025 at 4:30 p.m. ET.

How can investors access Dynavax's Wells Fargo conference presentation?

The presentation will be accessible through the 'Events & Presentations' page in the Investors section of Dynavax's website at investors.dynavax.com/events-presentations.

What are Dynavax's (DVAX) main commercial products?

Dynavax has two main commercial products: HEPLISAV-B vaccine for hepatitis B prevention in adults, and CpG 1018 adjuvant used in HEPLISAV-B and multiple COVID-19 vaccines.

Where is HEPLISAV-B vaccine approved for use?

HEPLISAV-B is approved in the United States, European Union, and United Kingdom for prevention of all known hepatitis B virus subtypes in adults 18 years and older.